

Matthias J Schnell

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1936108/publications.pdf>

Version: 2024-02-01

130
papers

7,375
citations

41323

49
h-index

62565

80
g-index

139
all docs

139
docs citations

139
times ranked

5823
citing authors

#	ARTICLE	IF	CITATIONS
1	Measles-based Zika vaccine induces long-term immunity and requires NS1 antibodies to protect the female reproductive tract. <i>Npj Vaccines</i> , 2022, 7, 43.	2.9	12
2	A Single Dose of the Deactivated Rabies-Virus Vected COVID-19 Vaccine, CORAVAX, Is Highly Efficacious and Alleviates Lung Inflammation in the Hamster Model. <i>Viruses</i> , 2022, 14, 1126.	1.5	2
3	Current vaccine strategies against SARS-CoV-2: Promises and challenges. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 150, 17-21.	1.5	7
4	Inactivated rabies virus vectored SARS-CoV-2 vaccine prevents disease in a Syrian hamster model. <i>PLoS Pathogens</i> , 2021, 17, e1009383.	2.1	24
5	A single dose of replication-competent VSV-vectored vaccine expressing SARS-CoV-2 S1 protects against virus replication in a hamster model of severe COVID-19. <i>Npj Vaccines</i> , 2021, 6, 91.	2.9	19
6	SARS-CoV-2 vaccines â€” the biggest medical research project of the 21st century. <i>Current Opinion in Virology</i> , 2021, 49, 52-57.	2.6	12
7	Tetravalent Rabies-Vectored Filovirus and Lassa Fever Vaccine Induces Long-term Immunity in Nonhuman Primates. <i>Journal of Infectious Diseases</i> , 2021, 224, 995-1004.	1.9	10
8	A Strategy to Detect Emerging Non-Delta SARS-CoV-2 Variants with a Monoclonal Antibody Specific for the N501 Spike Residue. <i>Diagnostics</i> , 2021, 11, 2092.	1.3	6
9	Rabies virus-based COVID-19 vaccine CORAVAXâ„¢ induces high levels of neutralizing antibodies against SARS-CoV-2. <i>Npj Vaccines</i> , 2020, 5, 98.	2.9	26
10	Lyssavirus Vaccine with a Chimeric Glycoprotein Protects across Phylogroups. <i>Cell Reports</i> , 2020, 32, 107920.	2.9	10
11	Rhabdoviruses as vectors for vaccines and therapeutics. <i>Current Opinion in Virology</i> , 2020, 44, 169-182.	2.6	17
12	Identification and Characterization of a Small-Molecule Rabies Virus Entry Inhibitor. <i>Journal of Virology</i> , 2020, 94, .	1.5	5
13	Rabies Little Virus Against Powerful Innate Immunity. , 2020, , 141-154.		0
14	Inactivated Rabies Virusâ€”Based Ebola Vaccine Preserved by Vaporization Is Heat-Stable and Immunogenic Against Ebola and Protects Against Rabies Challenge. <i>Journal of Infectious Diseases</i> , 2019, 220, 1521-1528.	1.9	12
15	Rabies-based vaccine induces potent immune responses against Nipah virus. <i>Npj Vaccines</i> , 2019, 4, 15.	2.9	28
16	A new recombinant rabies virus expressing a green fluorescent protein: A novel and fast approach to quantify virus neutralizing antibodies. <i>Biologicals</i> , 2019, 59, 56-61.	0.5	14
17	Avoiding preventable deaths: The scourge of counterfeit rabies vaccines. <i>Vaccine</i> , 2019, 37, 2285-2287.	1.7	22
18	Status of antiviral therapeutics against rabies virus and related emerging lyssaviruses. <i>Current Opinion in Virology</i> , 2019, 35, 1-13.	2.6	28

#	ARTICLE	IF	CITATIONS
19	A Recombinant Rabies Virus Expressing the Marburg Virus Glycoprotein Is Dependent upon Antibody-Mediated Cellular Cytotoxicity for Protection against Marburg Virus Disease in a Murine Model. <i>Journal of Virology</i> , 2019, 93, .	1.5	19
20	The spread and evolution of rabies virus: conquering new frontiers. <i>Nature Reviews Microbiology</i> , 2018, 16, 241-255.	13.6	191
21	Ebola Virus Localization in the Macaque Reproductive Tract during Acute Ebola Virus Disease. <i>American Journal of Pathology</i> , 2018, 188, 550-558.	1.9	33
22	Persistence of Lassa Virus Associated With Severe Systemic Arteritis in Convalescing Guinea Pigs (<i>Cavia porcellus</i>). <i>Journal of Infectious Diseases</i> , 2018, 219, 1818-1822.	1.9	13
23	Non-neutralizing antibodies elicited by recombinant Lassaâ€“Rabies vaccine are critical for protection against Lassa fever. <i>Nature Communications</i> , 2018, 9, 4223.	5.8	92
24	Retrograde axonal transport of rabies virus is unaffected by interferon treatment but blocked by emetine locally in axons. <i>PLoS Pathogens</i> , 2018, 14, e1007188.	2.1	37
25	Inactivated Recombinant Rabies Viruses Displaying Canine Distemper Virus Glycoproteins Induce Protective Immunity against Both Pathogens. <i>Journal of Virology</i> , 2017, 91, .	1.5	25
26	The Final (Oral Ebola) Vaccine Trial on Captive Chimpanzees?. <i>Scientific Reports</i> , 2017, 7, 43339.	1.6	19
27	Progress in Ebola Virus Vaccine Development. <i>Journal of Infectious Diseases</i> , 2017, 215, 1775-1776.	1.9	2
28	Ifit2 Is a Restriction Factor in Rabies Virus Pathogenicity. <i>Journal of Virology</i> , 2017, 91, .	1.5	33
29	One-Health: a Safe, Efficient, Dual-Use Vaccine for Humans and Animals against Middle East Respiratory Syndrome Coronavirus and Rabies Virus. <i>Journal of Virology</i> , 2017, 91, .	1.5	69
30	Toward an Effective Ebola Virus Vaccine. <i>Annual Review of Medicine</i> , 2017, 68, 371-386.	5.0	29
31	An Inactivated Rabies Virusâ€“Based Ebola Vaccine, FILORAB1, Adjuvanted With Glucopyranosyl Lipid A in Stable Emulsion Confers Complete Protection in Nonhuman Primate Challenge Models. <i>Journal of Infectious Diseases</i> , 2016, 214, S342-S354.	1.9	32
32	Keeping it in check: chronic viral infection and antiviral immunity in the brain. <i>Nature Reviews Neuroscience</i> , 2016, 17, 766-776.	4.9	49
33	Rabies Virus CVS-N2c Î”G Strain Enhances Retrograde Synaptic Transfer and Neuronal Viability. <i>Neuron</i> , 2016, 89, 711-724.	3.8	236
34	Preclinical Development of Inactivated Rabies Virusâ€“Based Polyvalent Vaccine Against Rabies and Filoviruses. <i>Journal of Infectious Diseases</i> , 2015, 212, S414-S424.	1.9	49
35	RABIES VIRUS REPLICATION AND PATHOGENESIS. , 2015, , 335-351.		0
36	Controlled viral glycoprotein expression as a safety feature in a bivalent rabies-ebola vaccine. <i>Virus Research</i> , 2015, 197, 54-58.	1.1	10

#	ARTICLE	IF	CITATIONS
37	Reverse genetics of Mononegavirales: How they work, new vaccines, and new cancer therapeutics. <i>Virology</i> , 2015, 479-480, 331-344.	1.1	61
38	Everything You Always Wanted to Know About Rabies Virus (But Were Afraid to Ask). <i>Annual Review of Virology</i> , 2015, 2, 451-471.	3.0	114
39	Rhabdovirus-Based Vaccine Platforms against Henipaviruses. <i>Journal of Virology</i> , 2015, 89, 144-154.	1.5	66
40	Recombinant rabies virus particles presenting botulinum neurotoxin antigens elicit a protective humoral response in vivo. <i>Molecular Therapy - Methods and Clinical Development</i> , 2014, 1, 14046.	1.8	9
41	Safety and serological response to a matrix gene-deleted rabies virus-based vaccine vector in dogs. <i>Vaccine</i> , 2014, 32, 1716-1719.	1.7	10
42	Small-Molecule Probes Targeting the Viral PPxY-Host Nedd4 Interface Block Egress of a Broad Range of RNA Viruses. <i>Journal of Virology</i> , 2014, 88, 7294-7306.	1.5	86
43	Alanine scanning of the rabies virus glycoprotein antigenic site III using recombinant rabies virus: Implication for post-exposure treatment. <i>Vaccine</i> , 2013, 31, 5897-5902.	1.7	14
44	Antibody Quality and Protection from Lethal Ebola Virus Challenge in Nonhuman Primates Immunized with Rabies Virus Based Bivalent Vaccine. <i>PLoS Pathogens</i> , 2013, 9, e1003389.	2.1	106
45	Rabies Virus Is Recognized by the NLRP3 Inflammasome and Activates Interleukin-1 β Release in Murine Dendritic Cells. <i>Journal of Virology</i> , 2013, 87, 5848-5857.	1.5	50
46	Comparison of Heterologous Prime-Boost Strategies against Human Immunodeficiency Virus Type 1 Gag Using Negative Stranded RNA Viruses. <i>PLoS ONE</i> , 2013, 8, e67123.	1.1	16
47	Interspecies protein substitution to investigate the role of the lyssavirus glycoprotein. <i>Journal of General Virology</i> , 2013, 94, 284-292.	1.3	11
48	Immune Clearance of Attenuated Rabies Virus Results in Neuronal Survival with Altered Gene Expression. <i>PLoS Pathogens</i> , 2012, 8, e1002971.	2.1	46
49	A replication-deficient rabies virus vaccine expressing Ebola virus glycoprotein is highly attenuated for neurovirulence. <i>Virology</i> , 2012, 434, 18-26.	1.1	28
50	Further characterization of the immune response in mice to inactivated and live rabies vaccines expressing Ebola virus glycoprotein. <i>Vaccine</i> , 2012, 30, 6136-6141.	1.7	27
51	Targeted single-neuron infection with rabies virus for transneuronal multisynaptic tracing. <i>Journal of Neuroscience Methods</i> , 2012, 209, 367-370.	1.3	9
52	A role for granulocyte macrophage colony-stimulating factor in the regulation of CD8+ T cell responses to rabies virus. <i>Virology</i> , 2012, 426, 120-133.	1.1	13
53	Rabies Virus as a Research Tool and Viral Vaccine Vector. <i>Advances in Virus Research</i> , 2011, 79, 139-164.	0.9	37
54	Immunization of mice with the non-toxic HC50 domain of botulinum neurotoxin presented by rabies virus particles induces a strong immune response affording protection against high-dose botulinum neurotoxin challenge. <i>Vaccine</i> , 2011, 29, 4638-4645.	1.7	20

#	ARTICLE	IF	CITATIONS
55	Proliferating cell nuclear antigen is required for loading of the SMCX/KMD5C histone demethylase onto chromatin. <i>Epigenetics and Chromatin</i> , 2011, 4, 18.	1.8	17
56	Rabies Virus (RV) Glycoprotein Expression Levels Are Not Critical for Pathogenicity of RV. <i>Journal of Virology</i> , 2011, 85, 697-704.	1.5	64
57	Inactivated or Live-Attenuated Bivalent Vaccines That Confer Protection against Rabies and Ebola Viruses. <i>Journal of Virology</i> , 2011, 85, 10605-10616.	1.5	75
58	A novel composite immunotoxin that suppresses rabies virus production by the infected cells. <i>Journal of Immunological Methods</i> , 2010, 353, 78-86.	0.6	13
59	Induction of Neutralizing Antibody Responses to Anthrax Protective Antigen by Using Influenza Virus Vectors: Implications for Disparate Immune System Priming Pathways. <i>Journal of Virology</i> , 2010, 84, 8300-8307.	1.5	20
60	Rabies Virus Infection Induces Type I Interferon Production in an IPS-1 Dependent Manner While Dendritic Cell Activation Relies on IFNAR Signaling. <i>PLoS Pathogens</i> , 2010, 6, e1001016.	2.1	93
61	Characterization of a Single-Cycle Rabies Virus-Based Vaccine Vector. <i>Journal of Virology</i> , 2010, 84, 2820-2831.	1.5	42
62	Attenuation of Rabies Virulence: Takeover by the Cytoplasmic Domain of Its Envelope Protein. <i>Science Signaling</i> , 2010, 3, ra5.	1.6	100
63	The cell biology of rabies virus: using stealth to reach the brain. <i>Nature Reviews Microbiology</i> , 2010, 8, 51-61.	13.6	302
64	Dendritic cells infected by recombinant rabies virus vaccine vector expressing HIV-1 Gag are immunogenic even in the presence of vector-specific immunity. <i>Vaccine</i> , 2010, 29, 130-140.	1.7	11
65	Replication-Deficient Rabies Virus-Based Vaccines Are Safe and Immunogenic in Mice and Nonhuman Primates. <i>Journal of Infectious Diseases</i> , 2009, 200, 1251-1260.	1.9	49
66	Lineage-Specific T-Cell Responses to Cancer Mucosa Antigen Oppose Systemic Metastases without Mucosal Inflammatory Disease. <i>Cancer Research</i> , 2009, 69, 3537-3544.	0.4	35
67	Intravenous Inoculation of a Bat-Associated Rabies Virus Causes Lethal Encephalopathy in Mice through Invasion of the Brain via Neurosecretory Hypothalamic Fibers. <i>PLoS Pathogens</i> , 2009, 5, e1000485.	2.1	35
68	Rabies virus-based vaccines elicit neutralizing antibodies, poly-functional CD8+ T cell, and protect rhesus macaques from AIDS-like disease after SIVmac251 challenge. <i>Vaccine</i> , 2009, 28, 299-308.	1.7	29
69	Interferon Response and Viral Evasion by Members of the Family Rhabdoviridae. <i>Viruses</i> , 2009, 1, 832-851.	1.5	46
70	Interferon- β expressed by a rabies virus-based HIV-1 vaccine vector serves as a molecular adjuvant and decreases pathogenicity. <i>Virology</i> , 2008, 382, 226-238.	1.1	48
71	Infection of monocytes or immature dendritic cells (DCs) with an attenuated rabies virus results in DC maturation and a strong activation of the NF κ B signaling pathway. <i>Vaccine</i> , 2008, 26, 419-426.	1.7	43
72	Immune modulating effect by a phosphoprotein-deleted rabies virus vaccine vector expressing two copies of the rabies virus glycoprotein gene. <i>Vaccine</i> , 2008, 26, 6405-6414.	1.7	46

#	ARTICLE	IF	CITATIONS
73	Cluster Formation and Rheology of Photoreactive Nanoparticle Dispersions. <i>Langmuir</i> , 2008, 24, 5299-5305.	1.6	10
74	The Glycoprotein and the Matrix Protein of Rabies Virus Affect Pathogenicity by Regulating Viral Replication and Facilitating Cell-to-Cell Spread. <i>Journal of Virology</i> , 2008, 82, 2330-2338.	1.5	77
75	Concepts in the pathogenesis of rabies. <i>Future Virology</i> , 2008, 3, 481-490.	0.9	141
76	Guanylyl Cyclase-Induced Immunotherapeutic Responses Opposing Tumor Metastases Without Autoimmunity. <i>Journal of the National Cancer Institute</i> , 2008, 100, 950-961.	3.0	48
77	PPEY Motif within the Rabies Virus (RV) Matrix Protein Is Essential for Efficient Virion Release and RV Pathogenicity. <i>Journal of Virology</i> , 2008, 82, 9730-9738.	1.5	76
78	Dominance of a Nonpathogenic Glycoprotein Gene over a Pathogenic Glycoprotein Gene in Rabies Virus. <i>Journal of Virology</i> , 2007, 81, 7041-7047.	1.5	58
79	The dynein light chain 8 binding motif of rabies virus phosphoprotein promotes efficient viral transcription. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 7229-7234.	3.3	122
80	Highly Attenuated Rabies Virus-Based Vaccine Vectors Expressing Simian-Human Immunodeficiency Virus89.6PEnv and Simian Immunodeficiency Virusmac239Gag Are Safe in Rhesus Macaques and Protect from an AIDS-Like Disease. <i>Journal of Infectious Diseases</i> , 2007, 195, 980-988.	1.9	29
81	Enhanced humoral HIV-1-specific immune responses generated from recombinant rhabdoviral-based vaccine vectors co-expressing HIV-1 proteins and IL-2. <i>Virology</i> , 2006, 344, 363-377.	1.1	28
82	siRNA targeting Vaccinia virus double-stranded RNA binding protein [E3L] exerts potent antiviral effects. <i>Virology</i> , 2006, 348, 489-497.	1.1	25
83	Human CD8+ cytotoxic T cell responses to adenovirus capsid proteins. <i>Virology</i> , 2006, 350, 312-322.	1.1	70
84	Rabies virus glycoprotein as a carrier for anthrax protective antigen. <i>Virology</i> , 2006, 353, 344-356.	1.1	37
85	A single immunization with a recombinant canine adenovirus expressing the rabies virus G protein confers protective immunity against rabies in mice. <i>Virology</i> , 2006, 356, 147-154.	1.1	38
86	Human T-Cell Responses to Vaccinia Virus Envelope Proteins. <i>Journal of Virology</i> , 2006, 80, 10010-10020.	1.5	39
87	Immunogenicity of Cytopathic and Noncytopathic Viral Vectors. <i>Journal of Virology</i> , 2006, 80, 6259-6266.	1.5	10
88	The application of reverse genetics technology in the study of rabies virus (RV) pathogenesis and for the development of novel RV vaccines. <i>Journal of NeuroVirology</i> , 2005, 11, 76-81.	1.0	44
89	Strong cellular and humoral anti-HIV Env immune responses induced by a heterologous rhabdoviral prime-boost approach. <i>Virology</i> , 2005, 331, 82-93.	1.1	44
90	A single immunization with a rhabdovirus-based vector expressing severe acute respiratory syndrome coronavirus (SARS-CoV) S protein results in the production of high levels of SARS-CoV-neutralizing antibodies. <i>Journal of General Virology</i> , 2005, 86, 1435-1440.	1.3	81

#	ARTICLE	IF	CITATIONS
91	Overexpression of Tumor Necrosis Factor Alpha by a Recombinant Rabies Virus Attenuates Replication in Neurons and Prevents Lethal Infection in Mice. <i>Journal of Virology</i> , 2005, 79, 15405-15416.	1.5	49
92	A Single Amino Acid Change in Rabies Virus Glycoprotein Increases Virus Spread and Enhances Virus Pathogenicity. <i>Journal of Virology</i> , 2005, 79, 14141-14148.	1.5	165
93	Budding of PPxY-Containing Rhabdoviruses Is Not Dependent on Host Proteins TGS101 and VPS4A. <i>Journal of Virology</i> , 2004, 78, 2657-2665.	1.5	95
94	Identification of viral genomic elements responsible for rabies virus neuroinvasiveness. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 16328-16332.	3.3	130
95	Immunogenicity Study of Glycoprotein-Deficient Rabies Virus Expressing Simian/Human Immunodeficiency Virus SHIV 89.6P Envelope in a Rhesus Macaque. <i>Journal of Virology</i> , 2004, 78, 13455-13459.	1.5	19
96	Rabies virus nucleoprotein as a carrier for foreign antigens. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 9405-9410.	3.3	31
97	Spliced Spleen Necrosis Virus Vector RNA Is Not Encapsidated: Implications for Retroviral Replication and Vector Design. <i>Molecular Therapy</i> , 2004, 9, 557-565.	3.7	3
98	In vitro growth and stability of recombinant rabies viruses designed for vaccination of wildlife. <i>Vaccine</i> , 2004, 23, 518-524.	1.7	42
99	Cell-type-specific gene delivery into neuronal cells in vitro and in vivo. <i>Virology</i> , 2003, 314, 74-83.	1.1	16
100	New approaches to the prevention and eradication of rabies. <i>Expert Review of Vaccines</i> , 2003, 2, 399-406.	2.0	53
101	Functional Human Immunodeficiency Virus Type 1 (HIV-1) Gag-Pol or HIV-1 Gag-Pol and Env Expressed from a Single Rhabdovirus-Based Vaccine Vector Genome. <i>Journal of Virology</i> , 2003, 77, 10889-10899.	1.5	60
102	Covalently Linked Human Immunodeficiency Virus Type 1 gp120/gp41 Is Stably Anchored in Rhabdovirus Particles and Exposes Critical Neutralizing Epitopes. <i>Journal of Virology</i> , 2003, 77, 12782-12794.	1.5	22
103	Second-Generation Rabies Virus-Based Vaccine Vectors Expressing Human Immunodeficiency Virus Type 1 Gag Have Greatly Reduced Pathogenicity but Are Highly Immunogenic. <i>Journal of Virology</i> , 2003, 77, 237-244.	1.5	96
104	Recombinant Rhabdoviruses as Potential Vaccines for HIV-1 and Other Diseases. <i>Current HIV Research</i> , 2003, 1, 229-237.	0.2	39
105	Rhabdovirus-Based Vectors with Human Immunodeficiency Virus Type 1 (HIV-1) Envelopes Display HIV-1-Like Tropism and Target Human Dendritic Cells. <i>Journal of Virology</i> , 2002, 76, 19-31.	1.5	31
106	Both Viral Transcription and Replication Are Reduced when the Rabies Virus Nucleoprotein Is Not Phosphorylated. <i>Journal of Virology</i> , 2002, 76, 4153-4161.	1.5	53
107	New Approaches to the Development of Live Attenuated Rabies Vaccines. <i>Hybridoma</i> , 2002, 21, 129-134.	0.6	17
108	HIV-1 vaccines: the search continues. <i>Clinics in Laboratory Medicine</i> , 2002, 22, 799-820.	0.7	3

#	ARTICLE	IF	CITATIONS
109	Overexpression of the Rabies Virus Glycoprotein Results in Enhancement of Apoptosis and Antiviral Immune Response. <i>Journal of Virology</i> , 2002, 76, 3374-3381.	1.5	184
110	Live and Killed Rhabdovirus-Based Vectors as Potential Hepatitis C Vaccines. <i>Virology</i> , 2002, 292, 24-34.	1.1	63
111	The rabies virus glycoprotein determines the distribution of different rabies virus strains in the brain. <i>Journal of NeuroVirology</i> , 2002, 8, 345-352.	1.0	51
112	Genetic engineering of live rabies vaccines. <i>Vaccine</i> , 2001, 19, 3543-3551.	1.7	65
113	Prostratin: activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART. <i>Blood</i> , 2001, 98, 3006-3015.	0.6	309
114	Mechanisms of Loss of Foreign Gene Expression in Recombinant Vesicular Stomatitis Viruses. <i>Virology</i> , 2001, 287, 427-435.	1.1	38
115	Viral vectors as potential HIV-1 vaccines. <i>FEMS Microbiology Letters</i> , 2001, 200, 123-129.	0.7	34
116	High level expression of a human rabies virus-neutralizing monoclonal antibody by a rhabdovirus-based vector. <i>Journal of Immunological Methods</i> , 2001, 252, 199-206.	0.6	26
117	Expression and Immunogenicity of Human Immunodeficiency Virus Type 1 Gag Expressed by a Replication-Competent Rhabdovirus-Based Vaccine Vector. <i>Journal of Virology</i> , 2001, 75, 8724-8732.	1.5	59
118	Overexpression of Cytochrome c by a Recombinant Rabies Virus Attenuates Pathogenicity and Enhances Antiviral Immunity. <i>Journal of Virology</i> , 2001, 75, 10800-10807.	1.5	61
119	Rabies Virus-Based Vectors Expressing Human Immunodeficiency Virus Type 1 (HIV-1) Envelope Protein Induce a Strong, Cross-Reactive Cytotoxic T-Lymphocyte Response against Envelope Proteins from Different HIV-1 Isolates. <i>Journal of Virology</i> , 2001, 75, 4430-4434.	1.5	59
120	Rhabdoviruses and the Cellular Ubiquitin-Proteasome System: a Budding Interaction. <i>Journal of Virology</i> , 2001, 75, 10623-10629.	1.5	185
121	Reinvestigation of the role of the rabies virus glycoprotein in viral pathogenesis using a reverse genetics approach. <i>Journal of NeuroVirology</i> , 2000, 6, 373-381.	1.0	108
122	A recombinant rabies virus expressing vesicular stomatitis virus glycoprotein fails to protect against rabies virus infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2000, 97, 14680-14685.	3.3	51
123	Recombinant Vesicular Stomatitis Virus Expressing Respiratory Syncytial Virus (RSV) Glycoproteins: RSV Fusion Protein Can Mediate Infection and Cell Fusion. <i>Virology</i> , 1999, 254, 81-91.	1.1	124
124	Requirement for a non-specific glycoprotein cytoplasmic domain sequence to drive efficient budding of vesicular stomatitis virus. <i>EMBO Journal</i> , 1998, 17, 1289-1296.	3.5	137
125	Generation of mucosal cytotoxic T cells against soluble protein by tissue-specific environmental and costimulatory signals. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1998, 95, 10814-10819.	3.3	112
126	Construction of a Novel Virus That Targets HIV-1-Infected Cells and Controls HIV-1 Infection. <i>Cell</i> , 1997, 90, 849-857.	13.5	229

#	ARTICLE	IF	CITATIONS
127	Normal Replication of Vesicular Stomatitis Virus without C Proteins. <i>Virology</i> , 1996, 216, 309-316.	1.1	75
128	Highly stable expression of a foreign gene from rabies virus vectors.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1996, 93, 7310-7314.	3.3	137
129	Foreign glycoproteins expressed from recombinant vesicular stomatitis viruses are incorporated efficiently into virus particles.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1996, 93, 11359-11365.	3.3	271
130	Polymerase Activity of in Vitro Mutated Rabies Virus L Protein. <i>Virology</i> , 1995, 214, 522-530.	1.1	103